Utama › Kanser Hipofaring › Michigan

Kajian klinikal Kanser Hipofaring di Michigan

5 kajian untuk Kanser Hipofaring sedang mencari peserta di lokasi di Michigan.

Bandar di Michigan

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
dan 8 lagi

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06589804

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
University of Michigan Rogel Cancer Center, Ann Arbor
Bronson Battle Creek, Battle Creek
dan 23 lagi

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
dan 60 lagi

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT02734537

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

McLaren Cancer Institute-Bay City, Bay City
McLaren Cancer Institute-Clarkston, Clarkston
Wayne State University/Karmanos Cancer Institute, Detroit
dan 8 lagi

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06532279

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Henry Ford Cancer Institute, Detroit

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT04198766

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.